미국 - 영어 - NLM (National Library of Medicine)

aleor dermaceuticals limited - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (fsh, lh) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. limitations of use: - safety and efficacy of testosterone topical solution in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been estab

이스라엘 - 영어 - Ministry of Health

cts ltd - testosterone - gel - testosterone 0.05 mg/sachet - testosterone - testosterone - testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

미국 - 영어 - NLM (National Library of Medicine)

deseret biologicals, inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 6 [hp_x] in 1 ml - for temporary relief of symptoms including weak libido, stress, memory loss, stomach discomfort and general joint pain.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms including weak libido, stress, memory loss, stomach discomfort and general joint pain.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

미국 - 영어 - NLM (National Library of Medicine)

asp cares - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection, usp is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. 1. known hypersensitivity to the drug 2. males with carcinoma of the breast 3. males with known or suspected carcinoma of the prostate gland 4. women who are or who may become pregnant 5. patients with serious cardiac, hepatic or renal disease controlled substa

미국 - 영어 - NLM (National Library of Medicine)

novitium pharma llc - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - 1. males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: - primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. safety and efficacy of methyltestosterone in men

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

besins healthcare ireland limited - testosterone undecanoate - solution for injection - testosterone

캐나다 - 영어 - Health Canada

sterimax inc - testosterone cypionate - liquid - 100mg - testosterone cypionate 100mg - androgens

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - testosterone, quantity: 0.0125 g - gel - excipient ingredients: ethanol; isopropyl myristate; purified water; carbomer 980; sodium hydroxide - indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - testosterone, quantity: 1.71 g - gel - excipient ingredients: ethanol; purified water; propylene glycol; diethylene glycol monoethyl ether; carbomer 980; trolamine; disodium edetate - testavan is indicated for use as testosterone replacement therapy for adult male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

미국 - 영어 - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - methyltestosterone 10 mg - 1. males androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: - primary hypogonadism (congenita or acquired) — testicular failure due to cryptohidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) if the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. safety and efficacy of methyltestosterone in men